NEUROVATION LABS INC — Department of Defense SBIR Phase II: AF193-CSO1

Description

Neurovation Labs (NL) is revolutionizing Post-traumatic Stress Disorder (PTSD) healthcare. PTSD is an incapacitating disorder affecting nearly 10% of the U.S. population, particularly military and veterans. NL is developing the first-ever viable biotechnology solution to PTSD, leveraging a groundbreaking biomarker discovery to develop two novel innovations—an objective, rapid diagnostic and a precision medication targeting the root of the disorder. During Phase I feasibility studies, NL successfully gained interest from USAF/ DoD stakeholders to join their Phase II prototype effort. NL’s lead stakeholder is AFSOC, 24th Special Operations Wing (SOW); supporting stakeholders are the 59th Medical Wing, Joint Base Pearl Harbor-Hickam, West Point, Navy Medical Center San Diego, and CENTCOM. During Phase II, NL will continue prototype development for both products and adapt them for defense use, including making our diagnostic portable and handheld for emergency response. To commercialize, NL identified a chemistry company partner, a retired Air Force General to join NL as an Advisor, and a private investor who intends to invest along with the Phase II award. NL’s dual PTSD solution may provide great value not just to the warfighter but also to the large suffering civilian population, ending the current PTSD epidemic as we know it.